All News
Filter News
Found 75,562 articles
-
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
3/28/2024
Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the full year ended December 31, 2023 and recent business highlights.
-
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
3/28/2024
Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
3/28/2024
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.
-
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
3/28/2024
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM) today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
3/28/2024
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent business highlights.
-
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
3/28/2024
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.
-
Dyadic Reports 2023 Full Year Results and Recent Company Progress
3/28/2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial result for the year end 2023 and highlighted recent Company progress.
-
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
3/28/2024
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced that it will be presenting at two upcoming investor conferences in Denver and New York.
-
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
3/27/2024
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) today announced a strategic pivot aimed at advancing its clinical-stage candidate stenoparib, a novel PARP/Tankyrase dual inhibitor, toward registration in advanced recurrent ovarian cancer, leveraging its DRP® platform to identify and enroll only the patients most likely to derive clinical benefit.
-
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
3/27/2024
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment.
-
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
3/27/2024
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID.
-
Biopharmaceuticals Contract Manufacturing Market Size To Hit USD 31.92 Bn By 2032
3/27/2024
According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.
-
Clinical Microbiology Market is Experiencing Significant Growth
3/27/2024
The global clinical microbiology market size was estimated at around USD 4.58 billion in 2023 and it is projected to hit around USD 7.73 billion by 2033.
-
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
3/27/2024
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid products for a wide range of applications, including wound care and dermatological conditions, highlights the safety advantages of its Microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Tevogen Bio Announces Series A-1 Preferred Stock Investment
3/27/2024
Tevogen Bio Holdings has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
-
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
3/27/2024
Moderna, Inc. announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline.
-
Stephanie Burke Named as VGXI's New Chief Accounting Officer
3/27/2024
VGXI, Inc., a leading contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, is pleased to announce the appointment of Stephanie Burke as the Chief Accounting Officer for VGXI.